RxDoctor Payments Data

Alfred Boyd, MD

Family Medicine · Shenandoah, TXNPI 1295774339

Payments from drug & device makers

$4,375in general payments, 2019–2025

Across 229 payments — averaging $19.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$544
  • Dexcom, Inc.$462
  • GSK$415
  • Inspire Medical Systems, Inc.$366
  • Lilly USA, LLC$337
  • Amgen$308
  • plus $2K from 34 others

What the payments were for

  • Food & beverage$4,375100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$4,375 in reported general payments places this provider in the 80th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$185,765
Medicare patients
454
Services billed
2,937

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide44$93,224
OzempicSemaglutide51$89,364
MounjaroTirzepatide41$83,578
EliquisApixaban46$64,814
JanuviaSitagliptin Phosphate40$48,035
JardianceEmpagliflozin29$46,237
XareltoRivaroxaban25$37,941
Trelegy ElliptaFluticasone/Umeclidin/Vilanter42$34,695
LinzessLinaclotide26$30,521
FarxigaDapagliflozin Propanediol16$25,400
Tresiba Flextouch U-100Insulin Degludec12$8,408
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog15$7,928
Breo ElliptaFluticasone/Vilanterol15$6,566
Lantus SolostarInsulin Glargine,hum.Rec.Anlog38$4,819
Atorvastatin Calcium545$4,651

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$337$176,80185 claims
Novo NordiskOzempic$544$89,36451 claims
PfizerEliquis$275$64,81446 claims
MerckJanuvia$60$48,03540 claims
Boehringer IngelheimJardiance$40$46,23729 claims
GSKTrelegy Ellipta, Breo Ellipta$415$41,26157 claims
AbbVieLinzess, Synthroid$33$32,71275 claims
AstraZenecaFarxiga$247$25,40016 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Shenandoah

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →